09:05 AM EST, 11/12/2024 (MT Newswires) -- ImmunityBio ( IBRX ) reported Q3 net loss Tuesday of $0.14 per diluted share, narrower than the loss of $0.19 a year earlier.

Two analysts polled by Capital IQ expected a loss of $0.18.

Revenue for the quarter ended Sept. 30 was $6.1 million, up from around $82,000 a year earlier.

Three analysts polled by Capital IQ expected $2.9 million.